FDA BREAKINGDrug Approval
FDA Approves New Anti-Seizure Medication for Treatment-Resistant Focal Epilepsy
FDA·Tuesday, March 18, 2025·US
The FDA has approved cenobamate (Xcopri) expanded indication for adults with focal onset impaired awareness seizures that have not responded to at least two prior anti-seizure medications.
Related Conditions
Share this article
Help others stay informed